CANINE COMPARATIVE ONCOLOGY & GENOMICS CONSORTIUM

Press Releases

Canine Comparative Oncology and Genomics Consortium and the Pfizer-CCOGC Biospecimen Repository Announces the ACCELERATED DISTRIBUTION of Biospecimen Samples

The Pfizer-CCOGC Biospecimen Repository has been open for release since September 2013. As part of its strategic effort to accelerate discovery, the Pfizer-CCOGC Biospecimen Repository has modified the process of biospecimen sample release and distribution. Most applications will no longer require scientific review or project disclosure. CCOCG President, Dr. Jaime Modiano said, “our experience to date indicates that investigators soliciting samples are conducting highly meritorious projects, and the results generated from these samples have led to important publications which have had significant, positive impact in the fields of cancer and genomics. To continue and expand these trends, we have streamlined the application process to make our high quality biospecimens more accessible and to make their release expeditious.” Quality control and assessment indicates that diagnostic accuracy for samples in the Pfizer-CCOGC Biospecimen Repository is exceptional, supporting high quality downstream applications for pathologic, genomic, and other analyses. The Pfizer-CCOGC Biospecimen Repository houses over 60,000 samples across seven spontaneously arising cancer histologies: osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas and

Click Here to Read More

Canine Comparative Oncology and Genomics Consortium and the Pfizer-CCOGC Biospecimen Repository Announces the Sale of 1000 Biospecimens in First Year and Completion of Quality Control and Assessment of Repository

Rockville, MD – The Pfizer-CCOGC Biospecimen Repository has been open for release since September 2013. In year one, the Pfizer-CCOGC Biospecimen Repository has sold 1000 samples to investigators. Each application is evaluated based on scientific merit. Quality control and assessment of randomly selected samples from the Pfizer-CCOGC Biospecimen Repository, representing 10% of all cases submitted, has been completed.  The diagnostic classification of almost 89% of submitted specimens was corroborated by in-depth re-review by a panel of independent veterinary pathologists. Secondly, the proportion of specimens yielding nucleic acid considered being of suitable quality for most downstream genomics applications was 89.4% for tumor DNA, 92.1% for tumor RNA and 99.5% for blood DNA. The Pfizer-CCOGC Biospecimen Repository currently houses over 60,000 samples across seven spontaneously arising cancer histologies: osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas and hemangiosarcoma. Samples available from each patient include: tumor and normal tissues (formalin fixed, snap frozen and OCT), as well as frozen serum, plasma, urine and whole blood (from both EDTA and PaxGene RNA

Click Here to Read More

Canine Comparative Oncology and Genomics Consortium and the Pfizer-CCOGC Biospecimen Repository Announce the Availability of Canine Cancer Patient Biospecimens for Scientific Study Effective October 29th 2012

Rockville, MD – Canine cancer patient biospecimens are now available for scientific use through the Canine Comparative Oncology and Genomics Consortium (CCOGC) and the Pfizer-CCOGC Biospecimen Repository. The CCOGC has created an infrastructure for the collection and banking of tissues from dogs with naturally occurring cancer to help researchers further the investigation into the inner workings of cancer in the domestic dog, as well as facilitate investigation into tumor types with broad translational relevance that can benefit both human and dog patients. The Pfizer-CCOGC Biospecimen Repository currently houses over 2,000 patient samples across seven spontaneously arising cancer histologies: osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas and hemangiosarcoma. Samples available from each patient include: tumor and normal tissues (formalin fixed, snap frozen and OCT), as well as frozen serum, plasma, urine and whole blood (from both EDTA and PaxGene RNA collection tubes). For more information about CCOGC and to apply for samples from the biorepository, please visit www.ccogc.net or contact us at biospecimens@ccogc.net CCOGC Background Formed in 2004,

Click Here to Read More

Canine Comparative Oncology and Genomics Consortium And the Pfizer-CCOGC Biospecimen Repository Announce the Availability of Canine Biospecimens for Scientific Study

Rockville, MD – Canine cancer biospecimens are now available to be released for scientific research through the Canine Comparative Oncology and Genomics Consortium (CCOGC) and the Pfizer-CCOGC Biospecimen Repository. Patient sample sets from canine cancer patients have been collected to build the repository and they are now available to help researchers further the investigation into the inner workings of cancer in many breeds, as well as facilitate investigation into tumor types with broad translational relevance that can benefit both human and veterinary patients. Seven spontaneously arising cancer histologies (osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas, hemangiosarcom) are currently banked.  Samples from each patient include: tumor tissue, normal tissue, serum, plasma, urine, whole blood, DNA, and RNA. In addition, the CCOGC has an established infrastructure for prospective sample collection should the banked samples not meet your research needs. For more information about CCOGC, applying for repository samples, or inquiring about prospective tissue collections, please visit our website at www.ccogc.net or contact us at administration@ccogc.net. CCOGC Background Formed in

Click Here to Read More